[go: up one dir, main page]

WO1993023035A3 - Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease - Google Patents

Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease Download PDF

Info

Publication number
WO1993023035A3
WO1993023035A3 PCT/EP1993/001099 EP9301099W WO9323035A3 WO 1993023035 A3 WO1993023035 A3 WO 1993023035A3 EP 9301099 W EP9301099 W EP 9301099W WO 9323035 A3 WO9323035 A3 WO 9323035A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
parkinson
disease
memory disorders
sexual dysfunction
Prior art date
Application number
PCT/EP1993/001099
Other languages
French (fr)
Other versions
WO1993023035A2 (en
Inventor
Robin Bradshaw Fears
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210576A external-priority patent/GB9210576D0/en
Priority claimed from GB929210594A external-priority patent/GB9210594D0/en
Priority claimed from GB929210595A external-priority patent/GB9210595D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to JP5519830A priority Critical patent/JPH07506823A/en
Priority to EP93912699A priority patent/EP0641202A1/en
Publication of WO1993023035A2 publication Critical patent/WO1993023035A2/en
Publication of WO1993023035A3 publication Critical patent/WO1993023035A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selective dopamine D3 receptor agonists and their use in therapy, inter alia, in the treatment of memory disorders.
PCT/EP1993/001099 1992-05-18 1993-05-04 Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease WO1993023035A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5519830A JPH07506823A (en) 1992-05-18 1993-05-04 Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
EP93912699A EP0641202A1 (en) 1992-05-18 1993-05-04 Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9210576.6 1992-05-18
GB929210576A GB9210576D0 (en) 1992-05-18 1992-05-18 Medical use
GB9210595.6 1992-05-18
GB929210594A GB9210594D0 (en) 1992-05-18 1992-05-18 Medical use
GB9210594.9 1992-05-18
GB929210595A GB9210595D0 (en) 1992-05-18 1992-05-18 Medical use

Publications (2)

Publication Number Publication Date
WO1993023035A2 WO1993023035A2 (en) 1993-11-25
WO1993023035A3 true WO1993023035A3 (en) 1994-03-03

Family

ID=27266192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/001099 WO1993023035A2 (en) 1992-05-18 1993-05-04 Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease

Country Status (4)

Country Link
EP (1) EP0641202A1 (en)
JP (1) JPH07506823A (en)
AU (1) AU4312593A (en)
WO (1) WO1993023035A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
FR2742149B1 (en) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med NOVEL 2-NAPHTAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
PT923551E (en) * 1996-08-27 2002-09-30 American Home Prod 4-AMINOETHOXY INDOLONE DERIVATIVES
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
EP1073636A1 (en) * 1998-04-13 2001-02-07 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JP2002518435A (en) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン Methods and compositions for the treatment or amelioration of female sexual dysfunction
CA2251255A1 (en) * 1998-10-20 2000-04-20 Mcgill University The use of dopaminergic agents in the management of sexual dysfunction
AR030557A1 (en) 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
DE10041479A1 (en) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition for the administration of N-0923
DE10359528A1 (en) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic
MXPA06013759A (en) * 2004-05-26 2007-02-08 Pfizer New indazole and indolone derivatives and their use as pharmaceuticals.
CN103347517B (en) 2010-08-11 2018-10-02 德雷克塞尔大学 D3 dopamine receptor agonists for the treatment of dyskinesias in Parkinson's disease
JP6607852B2 (en) 2013-10-28 2019-11-20 ドレクセル ユニバーシティ Therapeutic agents for attention disorders, cognitive disorders, and dementia related to neurodegenerative disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113964A1 (en) * 1982-12-07 1984-07-25 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
EP0299602A2 (en) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited Use of indolone derivatives for the preparation of medicaments for the treatment of Parkinsons disease
WO1991015513A1 (en) * 1990-04-06 1991-10-17 Institut National De La Sante Et De La Recherche Medicale Polypeptides with a dopaminergic receptor activity, nucleic acids coding for these polypeptides and use of these polypeptides to screen active substances on these polypeptides
WO1992000735A1 (en) * 1990-07-09 1992-01-23 Smith Kline & French Laboratories Limited Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113964A1 (en) * 1982-12-07 1984-07-25 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
EP0299602A2 (en) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited Use of indolone derivatives for the preparation of medicaments for the treatment of Parkinsons disease
WO1991015513A1 (en) * 1990-04-06 1991-10-17 Institut National De La Sante Et De La Recherche Medicale Polypeptides with a dopaminergic receptor activity, nucleic acids coding for these polypeptides and use of these polypeptides to screen active substances on these polypeptides
WO1992000735A1 (en) * 1990-07-09 1992-01-23 Smith Kline & French Laboratories Limited Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AHLENIUS, S. ET AL: "EFFECTS OF PERGOLIDE AND BROMOCRIPTINE ON MALE RAT SEXUAL BEHAVIOUR", J. NEURAL TRANSMISSION, vol. 54, 1982, pages 165 - 170 *
CLOSE, S.P. ET AL: "EFFECTS OF CLASSICAL AND NOVEL AGENTS IN A MPTP-INDUCED REVERSIBLE MODEL OF PARKINSON'S DISEASE", PSYCHOPHARMACOLOGY, vol. 102, no. 3, 1990, pages 295 - 300, XP000612744, DOI: doi:10.1007/BF02244093 *
FULLER, R.W. ET AL: "PERGOLIDE: A DOPAMINE AGONIST AT BOTH D1 AND D2 RECEPTORS", LIFE SCIENCES, vol. 49, no. 13, 1991, pages 925 - 930, XP023721244, DOI: doi:10.1016/0024-3205(91)90074-L *
IZQUIERDO, I.: "DOPAMINE RECEPTORS IN THE CAUDATE NUCLEUS AND MEMORY PROCESSES", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 13, no. 1, January 1992 (1992-01-01), pages 7 - 8, XP025955002, DOI: doi:10.1016/0165-6147(92)90004-P *
KOLLER, W. ET AL: "QUINPIROLE HYDROCHLORIDE, A POTENTIAL ANTI-PARKINSONIAN DRUG", NEUROPHARMACOLOGY, vol. 26, no. 8, August 1987 (1987-08-01), pages 1031 - 1036 *
LAMBERTS, S.W. ET AL: "A COMPARISON OF THE EFFICACY AND SAFETY OF PERGOLIDE AND BROMOCRIPTINE IN THE TREATMENT OF HYPERPROLACTINAEMIA", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 72, no. 3, March 1991 (1991-03-01), pages 635 - 641 *
MCGURK, S.R. ET AL: "DOPAMINERGIC DRUGS REVERSE THE IMPAIRMENT OF RADIAL-ARM MAZE PERFORMANCE CAUSED BY LESIONS INVOLVING THE CHOLINERGIC MEDIAL PATHWAY", NEUROSCIENCE, vol. 50, no. 1, 1992, pages 129 - 135, XP024385904, DOI: doi:10.1016/0306-4522(92)90387-H *
MUSCAT, R. ET AL: "ANTIDEPRESSANT-LIKE EFFECTS OF DOPAMINE AGONISTS IN AN ANIMAL MODEL OF DEPRESSION", BIOLOGICAL PSYCHIATRY, vol. 31, no. 9, 1 May 1991 (1991-05-01), pages 937 - 946, XP024250874, DOI: doi:10.1016/0006-3223(92)90119-K *
PACKARD, M.G. ET AL: "DISSOCIATION OF HIPPOCAMPUS AND CAUDATE NUCLEUS MEMORY SYSTEMS BY POSTTRAINING INTRACEREBRAL INJECTION OF DOPAMINE AGONISTS", BEHAVIOURAL NEUROSCIENCE, vol. 105, no. 2, April 1991 (1991-04-01), pages 295 - 306 *
PACKARD, M.G. ET AL: "MEMORY FACILITATION PRODUCED BY DOPAMINE AGONISTS: ROLE OF RECEPTOR SUBTYPE AND MNEMONIC REQUIREMENTS", PHARMACOLOGY BIOCHEMISTRY & BEHAVIOUR, vol. 33, no. 3, 1989, pages 511 - 518, XP025851515, DOI: doi:10.1016/0091-3057(89)90378-X *
POMERANTZ, S.M.: "QUINEROLANE (LY163502), A D2 DOPAMINE RECEPTOR AGONIST, ACTS CENTRALLY TO FACILITATE PENILE ERECTIONS OF MALE RHESUS MONKEYS", PHARMACOLOGY BIOCHEMISTRY & BEHAVIOUR, vol. 39, no. 1, 1991, pages 123 - 128, XP023808720, DOI: doi:10.1016/0091-3057(91)90408-T *
SOKOLOFF, P. ET AL: "PHARMACOLOGY OF HUMAN DOPAMINE D3 RECEPTOR EXPRESSED IN A MAMMALIAN CELL LINE: COMPARISON WITH D2 RECEPTOR", EUROPEAN JOURNAL OF PHARMACOLOGY, MOLECULAR PHARMACOLOGY SECTION, vol. 225, no. 4, 1992, pages 331 - 337, XP023861743, DOI: doi:10.1016/0922-4106(92)90107-7 *
SOKOLOFF, PIERRE ET AL: "LOCALIZATION AND FUNCTION OF THE DOPAMINE D3 RECEPTOR", ARZNEIMITTEL FORSCHUNG, vol. 42(I), no. 2A, February 1992 (1992-02-01), pages 224 - 230 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Also Published As

Publication number Publication date
JPH07506823A (en) 1995-07-27
EP0641202A1 (en) 1995-03-08
WO1993023035A2 (en) 1993-11-25
AU4312593A (en) 1993-12-13

Similar Documents

Publication Publication Date Title
WO1993023035A3 (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
CA2269698A1 (en) Agent for treating neurodegenerative disorders
CA2264895A1 (en) Device and method for treating ophthalmic diseases
CA2326804A1 (en) Compounds with activity on muscarinic receptors
EP0859637A4 (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
KR100246065B1 (en) Substituted 3-aminoquinuclidines
IS7747A (en) Spirol [1-azabicyclo [2.2.2] octane-3,2 '(3'H) -furo [2,3-b] pyridine] for use in the treatment of psychiatric disorders and cognitive disorders
BG104476A (en) Therapeutical form for tolterodin with controlled release
EP1027011A4 (en) Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
IL108285A0 (en) Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
AU3537893A (en) Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
EE04905B1 (en) Use of Pidasidino [4,5-b] Indole-1-Acetamide Derivatives for the Preparation of Medicines for the Treatment of Disorders Associated with Peripheral Benzodiazepine Receptor Dysfunction
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
CA2347863A1 (en) Treatment of disorders of the outer retina
AU3987593A (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
NO984572D0 (en) Use of 2,5-dihydroxybenzenesulfone derivatives for the manufacture of drugs intended for normalization of endothelial function, for the treatment of sexual dysfunction and vascular complications in diabetes, as well as vascular disorders of
WO1992015304A3 (en) Kappa receptor agonists in the treatment of cerebral ischaemia
AU4856600A (en) Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
AU2110095A (en) Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993912699

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 338497

Date of ref document: 19941130

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1993912699

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993912699

Country of ref document: EP